Cardiovascular complications of COVID-19
https://doi.org/10.21292/2078-5658-2020-17-4-14-22
Abstract
The objective: based on publications to provide up-to-date information on the frequency, basic variants and predictive significance of cardiovascular complications of the coronavirus infection caused by SARS-CoV-2.
Results: the article identifies variants of cardiovascular disorders in COVID-19 caused by various comorbidities in particular hypertension, specific virus-associated myocardial damage, and side effects of medications. It analyzes the role of angiotensin-converting enzyme 2 type II receptors during infection with the coronavirus and potential changes in the renin–angiotensin–aldosterone system including in patients receiving angiotensin-converting enzyme inhibitors or blockers of angiotensin receptors. The data on the frequency and prognostic role of arrhythmias, virus-associated myocardial damage and heart failure, the risk of ischemia, and myocardial infarction are presented. The adverse cardiovascular events of drugs of different groups prescribed for treatment of COVID-19 and possible drug interactions are described. The current recommendations for cardiotonic and cardioprotective therapy in patients with cardiovascular complications are analyzed.
Conclusion. The SARS-Cov-2 virus has a pronounced cardiac tropic effect which requires maximum cardiac alertness in the treatment of patients in this category, timely use of electrocardiography, echocardiography, control of biomarkers of myocardial damage and tension, as well as a reasonable use of cardiotonic and cardioprotective drugs.
About the Authors
I. A. Kozlov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Igor A. Kozlov - Regional Research Clinical Institute, Doctor of Medical Sciences, Professor, Professor of Anesthesiology and Intensive Care Faculty for Doctors' Professional Development.
61/2, Schepkina St., Moscow, 129110.
I. N. Tyurin
City Clinical Hospital no. 40, Moscow Health Department; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Igor N. Tyurin - Candidate of Medical Sciences, Deputy Head Physician, City Clinical Hospital no. 40.
7, Kasatkin St., Moscow, 129301.
References
1. Аvdeykin S.N., Tyurin I.N., Kozlov I.А. Management of hemodynamics in severe community acquired pneumonia, complicated by acute respiratory distress syndrome. Meditsinsky Alfavit. 2018, vol. 2, no. 18, pp. 19-28. (In Russ.)
2. Аnesteziologo-reanimatsionnoe obespechenie patsientov s novoy koronavirusnoy infektsiey COVID-19: Metodicheskie rekomendatsii. [Anesthesiology and resuscitation support for patients with the new coronavirus infection of COVID-19. Guidelines]. The official website of the Russian Federation of Anesthesiologists and Reanimatologists. http://www.far.org.ru/recomendation.
3. Bautin А.E., Osovskikh V.V. Acute right ventricular failure. Messenger of Anesthesiology and Resuscitation, 2018, vol. 15, no. 5, pp. 74-86. (In Russ.) doi: https://doi.org/10.21292/2078-5658-2018-15-5-74-86.
4. Belova Yu.N., Tarasova А.А., Ostreykov I.F. Efficiency of cardiotropic therapy in neonatal infants with posthypoxic myocardial damage. Obschaya Reanimatologiya, 2011, vol. 7, no. 4, pp. 38-42. (In Russ.) doi: https://doi.org/10.15360/1813-9779-2011-4-38.
5. Eremenko А.А. Pharmacological therapy of acute heart failure: what is available now and what is expected in future Messenger of Anesthesiology and Resuscitation, 2020, vol. 17, no. 2, pp. 29‒37.(In Russ.) doi: 10.21292/2078-5658-2020-17-2-29-37.
6. Kozlov I.А., Tyurin I.N. Septic cardiopathy: disputable issues and prospects. Messenger of Anesthesiology and Resuscitation, 2020, vol. 17, no. 2, pp. 49-58. (In Russ.) doi: 10.21292/2078-5658-2020-17-2-49-58.
7. Lomivorotov V.V., Lomivorotov V.N. Perioperative myocardial injury and infarction. Messenger of Anesthesiology and Resuscitation, 2019, vol. 16, no. 2, pp. 51-56. (In Russ.) doi: 10.21292/2078-5658-2019-16-2-51-56.
8. The official website of the American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
9. The official website of the European Society of Cardiology. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.
10. The official website of the Russian Cardiology Society. https://scardio.ru/news/novosti_obschestva/lechenie_iapf_ili_bra_vo_vremya_pandemii_covid19/
11. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann. Saudi Med., 2016, vol. 36, no. 1, pp. 78‒80. doi: 10.5144/0256‒4947.2016.78.
12. Aghagoli G., Gallo M.B., Soliman L.B. et al. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. J. Card. Surg., 2020, Apr. 19, doi: 10.1111/jocs.14538.
13. Burchill L.J., Velkoska E., Dean R.G. et al. Combination rennin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin. Sci. (Lond)., 2012, vol. 123, no. 11, pp. 649‒558. doi: 10.1042/CS20120162.
14. Chen C., Zhou Y., Wang D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz, 2020, vol. 45, no. 3, pp. 230‒232. doi: 10.1007/s00059-020-04909-z.
15. de Abajo F.J., Rodríguez-Martín S., Lerma V. et al. Use of rennin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet, 2020, vol. 14, pp. 1705‒1714. doi: 10.1016/S0140-6736(20)31030-8. PMID: 32416785.
16. Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol., 2020, vol. 75, no. 18, pp. 2352‒2371. doi: 10.1016/j.jacc.2020.03.031.
17. Ferrario C.M., Jessup J., Chappell M.C. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation, 2005, vol. 111, no. 20, pp. 2605‒2610. doi: 10.1161/CIRCULATIONAHA.104.510461.
18. Gaddi A.V., Galuppo P., Yang J. Creatine phosphate administration in cell energy impairment conditions: a summary of past and present research. Heart Lung. Circ., 2017, vol. 26, no. 10, pp. 1026‒1035. doi: 10.1016/j.hlc.2016.12.020.
19. Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol., 2020, vol. 27, pp. e201017. doi: 10.1001/jamacardio.2020.1017.
20. Gurwitz D. Angiotensin receptor blokers as tentative SARS-CoV-2. Therapeutic Drug. Dev. Res., 2020, Mar 4; 10.1002/ddr.21656. doi: 10.1002/ddr.21656. URL: researchgate.net.
21. Huang C., Wang Y., Li X. et al. Сlinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, pp. 497‒506. doi: 10.1016/S0140-6736(20)30183-5.
22. Inciardi R.M., Lupi L., Zaccone G. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol., 2020, Mar 27. doi: 10.1001/jamacardio.2020.1096.
23. Kochi A.N., Tagliari A.P., Forleo G.B. et al. Cardiac and arrhythmic complications in patients with COVID-19. J. Cardiovasc. Electrophysiol., 2020, vol. 31, no. 5, pp. 1003‒1008. doi: 10.1111/jce.14479.
24. Kwong J.C., Schwartz K.L., Campitelli M.A. et al. Acute myocardial infarction after laboratory‒confirmed influenza infection. N. Engl. J. Med., 2018, vol. 378, no. 4, pp. 345‒353. doi: 10.1056/NEJMoa1702090. PMID:29365305.
25. Li B., Yang J., Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol., 2020, vol. 109, no. 5, pp. 531‒538. doi: 10.1007/s00392-020-01626-9.
26. Long B., Brady W.J., Koyfman A. et al. Cardiovascular complications in COVID-19. Am. J. Emerg. Med., 2020, Apr. 18, pp. 1‒4. doi: 10.1016/j.ajem.2020.04.048.
27. Mehra M.R., Desai S.S., Ruschitzka F. et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, 2020, Published Online May 22. doi: https://doi.org/10.1016/S0140-6736(20)31180-6.
28. Niu L., An X.J., Tian J. et al. 124 cases of clinical analysis of children with viral myocarditis. Eur. Rev. Med. Pharmacol. Sci., 2015, vol. 19, no. 15, pp. 2856‒2859. PMID: 26241540.
29. Oudit G.Y., Kassiri Z., Jiang C. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Invest., 2009, vol. 39, no. 7, pp. 618‒25. doi: 10.1111/j.1365‒2362.2009.02153.x.
30. Ruan Q., Yang K., Wang W. et al. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens. Care Med., 2020, vol. 6, pp. 1‒4. doi: 10.1007/s00134-020-06028-z.
31. Shi S., Qin M., Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol., 2020, vol. 25, pp. e200950. doi: 10.1001/jamacardio.2020.0950.
32. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, vol. 323, no. 11, pp. 1061‒1069. doi: 10.1001/jama.2020.1585.
33. Welt F.G.P., Shah P.B., Aronow H.D. et al. American College of Cardiology’s Interventional Council and the Society for Cardiovascular Angiography and Interventions. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI. J. Am. Coll. Cardiol., 2020, vol. 75, no. 18, pp. 2372‒2375. doi: 10.1016/j.jacc.2020.03.021.
34. Williams B., Zhang Y. Hypertension, rennin-angiotensin-aldosterone system inhibition, and COVID-19. Lancet, 2020, May 18. doi:10.1016/s0140-6736(20)31131-4.
35. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med., 2020, vol. 8, no. 4, pp. 420‒422. doi: 10.1016/S2213-2600(20)30076-X.
36. Yang C., Jin Z. An acute respiratory infection runs into the most common noncommunicable epidemic ‒ COVID-19 and Cardiovascular Diseases. JAMA Cardiol., 2020, vol. 25. doi: 10.1001/jamacardio.2020.0934.
37. Yu C.M., Wong R.S., Wu E.B. et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad. Med. J., 2006, vol. 82 (964), pp. 140‒144. doi: 10.1136/pgmj.2005.037515.
38. Zeng J., Huang J., Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital. Intens. Care Med., 2020, vol. 11, pp. 1‒3. doi: 10.1007/s00134-020-05993-9.
39. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, vol. 395 (10229), pp. 1054‒1062. doi: 10.1016/S0140-6736(20)30566-3.
40. Zhu H., Rhee J.W., Cheng P. et al. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Curr. Cardiol. Rep., 2020, vol. 22, no. 5, pp. 32, doi: 10.1007/s11886-020-01292-3.
Review
For citations:
Kozlov I.A., Tyurin I.N. Cardiovascular complications of COVID-19. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2020;17(4):14-22. (In Russ.) https://doi.org/10.21292/2078-5658-2020-17-4-14-22
Email this article 